Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and tolerability of a new multivalent pneumococcal vaccine called PG4 in healthy infants. The study compares this new vaccine to the currently used 20-valent pneumococcal conjugate vaccine 20vPnC to see how well they protect against infections like pneumonia, meningitis, and ear infections caused by Streptococcus pneumoniae. The trial is a Phase 3, randomized, double-blinded study involving about 2400 infants around 2 months old. Participants will be randomly assigned to receive either the new PG4 vaccine or the 20vPnC vaccine. Both vaccines are given as injections into the left thigh muscle at 2, 4, 6, and between 12 to 15 months of age. The study lasts about 16 to 19 months, during which infants will have six clinic visits and one phone call to monitor their health and any side effects. During these visits, parents or legal guardians will report any local reactions, systemic events, or other adverse effects experienced by the infant after each vaccine dose. Researchers will track events occurring within seven days after each dose, as well as serious adverse events up to six months following the last dose. The goal is to understand the safety profile of the new vaccine compared to the existing one over the course of the study period.